LAWRENCEVILLE, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular ...
Early this month, at the end of the International Liver Cancer Association (ILCA) conference in Hong Kong, journalists from Southeast Asia gathered to hear good news from doctors and executives of ...
Dr. Abou-Alfa and Prof. Lencioni have been involved in the development of Celsion’s lead product ThermoDox® for the treatment of HCC, or primary liver cancer. A review of the data supporting Celsion’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results